Iruplinalkib tablets

DRUG3 trials

Sponsors

Henan Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Peking University Shenzhen Hospital

Conditions

ALKIruplinalkibLorlatinibNSCLCNon-Small Cell Lung CancerObservational StudyReal-world Study

Early Phase 1

An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer

RecruitingNCT06436885

Henan Cancer HospitalNon-Small Cell Lung Cancer

Start: 2024-02-28End: 2025-12-31Target: 39Updated: 2024-05-31

Phase 2

Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors

Not yet recruitingNCT07330076

Tianjin Medical University Cancer Institute and HospitalNSCLC

Start: 2026-01-06End: 2031-12-31Target: 28Updated: 2026-01-09

Unknown Phase

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

RecruitingNCT07374614

Peking University Shenzhen HospitalALK, Iruplinalkib, Lorlatinib +3

Start: 2026-01-31End: 2028-12-31Target: 20Updated: 2026-01-29